Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,265
archived clinical trials in
Rheumatoid Arthritis

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Kansas City, KA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Kansas City, KA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Metairie, LA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Metairie, LA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Lebanon, NH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lebanon, NH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Albuquerque, NM
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albuquerque, NM
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Ponca City, OK
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ponca City, OK
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Mountlake Terrace, WA
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis
Multi-center, Randomized, Double-blind, Parallel Group Study of the Safety, Disease Remission & Prevention of Structural Joint Damage During Treatment With Tocilizumab as a Monotherapy & in Combination With Methotrexate Versus Methotrexate in Pts With Early Moderate to Severe Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis
An Open-label, Multi-center, One Sequence Cross-over Drug Interaction Study to Investigate the Effect of Tocilizumab (TCZ, RO4877533) on the Pharmacokinetics and Pharmacodynamics of an Oral Contraceptive (OC) in Female Patients With Active Rheumatoid Arthritis (RA)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis
A Prospective, Multi-center Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care.
Status: Archived
Trial Information Support Line
mi
from
South San Francisco, CA
An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis
A Prospective, Multi-center Non-interventional Observational Study to Evaluate the Safety and Effectiveness of MabThera® (Rituximab) Within the First 6 Months of Treatment in Patients With Severe Active Rheumatoid Arthritis in Routine Care.
Status: Archived
Updated: 1/1/1970
Trial Information Support Line
mi
from
South San Francisco, CA
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines
Status: Archived
Trial Information Support Line
mi
from
South San Francisco, CA
An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)
Naturalistic Prospective Non-interventional Study on Rheumatoid Arthritis (RA) Patients Treated With Rituximab According to Local Treatment Guidelines
Status: Archived
Updated: 1/1/1970
Trial Information Support Line
mi
from
South San Francisco, CA
Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
Status: Archived
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Low Density Lipoprotein Cholesterol (CLDL) as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
cLDL as a Cardiovascular Disease Risk Factor in Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Peoria, AZ
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Peoria, AZ
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Little Rock, AR
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Little Rock, AR
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Newington, CT
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Newington, CT
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Coeur D'Alene, ID
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Centralia, IL
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Centralia, IL
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Jackson, MS
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Jackson, MS
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Omaha, NE
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Omaha, NE
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Lebanon, NH
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lebanon, NH
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
West Orange, NJ
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charlotte, NC
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A Study of Tocilizumab [RoActemra/Actemra] Versus Adalimumab in Patients With Rheumatoid Arthritis
A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms During Monotherapy Treatment With Tocilizumab 8 mg/kg Intravenously Versus Adalimumab 40 mg Subcutaneously in Patients With Rheumatoid Arthritis
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH